The Phase 2, double - blind trial enrolled 142 patients with advanced melanoma who had not received prior therapy. (sciencedaily.com)
The patients were all high risk and had received many prior therapies. (cancernetwork.com)
The median number of prior therapies for these patients was three; all the patients had been treated previously with at least one other EGFR TKI therapy, and most patients receiving chemotherapy as well. (sciencedaily.com)